| HOME >> BIOLOGY >> TECHNOLOGY |
CAMBRIDGE, Mass., Oct. 4 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the election of Jeffrey M. Leiden, M.D., Ph.D., to its Board of Directors. Dr. Leiden, a Managing Director at Clarus Ventures, a life sciences venture capital firm, has a distinguished career of more than 20 years of experience in the biomedical and pharmaceutical sectors. Prior to joining Clarus, Dr. Leiden served as President and Chief Operating Officer of the Global Pharmaceutical Business of Abbott Laboratories.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
"It is a pleasure to have Dr. Leiden join the Millennium Board of Directors," said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. "We believe his diverse pharmaceutical and scientific experience will enable him to help guide our continued growth and success in our mission of delivering vital medicines to patients."
Prior to joining Abbott Laboratories in 2000, Dr. Leiden was the Elkan R. Blout Professor of Biological Sciences at Harvard School of Public Health, as well as Professor of Medicine at Harvard Medical School. Before his career at Harvard, he served as Professor of Medicine and Pathology and Chief of Cardiology at the University of Chicago, School of Medicine. Dr. Leiden has also co-founded several biotechnology firms.
"I'm delighted to join Millennium's Board of Directors and begin
supporting Millennium's management in continuing to build a leading
biopharmaceutical company," said Dr. Leiden. "I look forward to utilizing
my experiences and knowledge to further the Company's success and deli
'/>"/>
| SOURCE Millennium Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |